| Title |
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
|
|---|---|
| Published in |
Investigational New Drugs, May 2013
|
| DOI | 10.1007/s10637-013-9973-4 |
| Pubmed ID | |
| Authors |
K. H. Park, J. H. Sohn, S. Lee, J. H. Park, S. Y. Kang, H. Y. Kim, I. H. Park, Y. H. Park, Y. H. Im, H. J. Lee, D. S. Hong, S. Park, S. H. Shin, H. C. Kwon, J. H. Seo |
| Abstract |
A pegylated form of recombinant granulocyte-colony stimulating factor (G-CSF) was developed for prophylactic use in breast cancer. The aim of this study was to evaluate the efficacy and safety of once-per-cycle DA-3031 in patients receiving chemotherapy for breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 18% |
| Student > Doctoral Student | 5 | 11% |
| Student > Bachelor | 4 | 9% |
| Professor | 3 | 7% |
| Lecturer | 3 | 7% |
| Other | 12 | 27% |
| Unknown | 9 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Psychology | 2 | 5% |
| Immunology and Microbiology | 1 | 2% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 5 | 11% |
| Unknown | 13 | 30% |